Status:
UNKNOWN
Effect of Dapagliflozin on LV Remodeling Post AMI
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The overall hypothesis of the study is that Dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction.
Detailed Description
In patients with heart failure, with or without diabetes, SGLT2i have shown to decrease remodeling. However, this has not been tested in patients following an acute myocardial infarction. Acute myoca...
Eligibility Criteria
Inclusion
- Acute myocardial infarction treated within the 24 hours of beginning of symptoms
- Signed informed consent
- SBP \> 90 mmHg
- Age \>= 18 years
Exclusion
- Glomerular Filtration Rate \< 30 ml/min/1.73 m2.
- Pregnant or lactating woman
- Cancer or life-threatening condition
- Use of continuous parental inotropic agents
- Psychiatric disease incompatible with being in study.
- Any contraindication to MRI procedures.
- Any other medical or physical condition considered to be inappropriate by a study physician
- Scheduled for a PCI or CABG within the next 6 months
- Hemodynamic unstability
- Currently on any SGLT2i
- One or more episodes of severe hypoglicemia
- Acute urinary or genital infection
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04783870
Start Date
March 3 2021
End Date
December 31 2024
Last Update
March 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Cardiología, Centro Médico Nacional Siglo XXI
Mexico City, Mexico, 06720